Drug:
Reaction: THERAPY INTERRUPTED
20260101 - 20261231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 26897235 |
US |
2 | |
Malaise, Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 402 | 26897240 |
US |
2 | |
Therapy interrupted, Product physical issue, |
||||
ICOSAPENT ETHYL, |
||||
| 403 | 26897241 |
US |
69 | 2 |
Vomiting, Flatulence, Eructation, Diarrhoea, Therapy interrupted, Insurance issue, Poor quality product administered, Product taste abnormal, Product physical issue, Product odour abnormal, |
||||
ICOSAPENT ETHYL, ICOSAPENT ETHYL, ICOSAPENT ETHYL, |
||||
| 404 | 26897500 |
US |
53 | 1 |
Rheumatoid arthritis, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 405 | 26906320 |
1 | ||
Hypotension, Therapy interrupted, |
||||
LENALIDOMIDE, NALOXEGOL OXALATE, |
||||
| 406 | 26906412 |
77 | 1 | |
Pulmonary embolism, Therapy interrupted, |
||||
LENALIDOMIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, SULFAMETHOXAZOLE AND TRIMETHOPRIM, CYCLOBENZAPRINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LISINOPRIL, NITROGLYCERIN, ROSUVASTATIN, |
||||
| 407 | 26911432 |
70 | 2 | |
Haemoglobin decreased, Therapy interrupted, |
||||
AMBRISENTAN, SOTATERCEPT-CSRK, |
||||
| 408 | 26911829 |
68 | 1 | |
Generalised oedema, Therapy interrupted, Contusion, |
||||
LENALIDOMIDE, |
||||
| 409 | 26911831 |
78 | 2 | |
Loss of consciousness, Pulmonary embolism, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 410 | 26911863 |
73 | 1 | |
Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 411 | 26911866 |
68 | 2 | |
Bacterial infection, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 412 | 26911867 |
79 | 2 | |
Abdominal pain, Pyrexia, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 413 | 26911894 |
75 | 2 | |
Hip fracture, Therapy interrupted, |
||||
ABALOPARATIDE, |
||||
| 414 | 26886595 |
US |
2 | |
Parathyroidectomy, Pain, Therapy interrupted, Insurance issue, |
||||
CERTOLIZUMAB PEGOL, CLOMIPHENE CITRATE, DEXAMETHASONE SODIUM PHOSPHATE, FOLIC ACID, |
||||
| 415 | 26886697 |
US |
1 | |
Cardiac operation, Therapy interrupted, Blood cholesterol increased, |
||||
EVOLOCUMAB, |
||||
| 416 | 26887031 |
US |
60 | 1 |
Colonoscopy, Gait disturbance, Spinal operation, Eczema, Intentional product misuse, Musculoskeletal disorder, Therapy interrupted, Eczema eyelids, Sensitivity to weather change, Psoriasis, |
||||
APREMILAST, APREMILAST, APREMILAST, |
||||
| 417 | 26887221 |
CA |
43 | |
Tendon rupture, Frequent bowel movements, Harvey-Bradshaw index increased, Abdominal distension, Diarrhoea, Fatigue, Therapy interrupted, Inappropriate schedule of product administration, Overdose, Therapy change, Off label use, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 418 | 26887231 |
US |
||
Nephrolithiasis, Therapy interrupted, |
||||
BUROSUMAB, FISH OIL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 419 | 26887308 |
US |
2 | |
Psoriatic arthropathy, Nasopharyngitis, Therapy interrupted, Gastric infection, Hypertension, COVID-19, Product dose omission issue, Therapy non-responder, |
||||
APREMILAST, APREMILAST, ATENOLOL, LOSARTAN POTASSIUM, LOSARTAN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 420 | 26887705 |
US |
2 | |
Psoriatic arthropathy, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 421 | 26887771 |
US |
73 | 2 |
Feeling abnormal, Therapy interrupted, Pain, Fatigue, |
||||
DENOSUMAB, |
||||
| 422 | 26887784 |
US |
58 | 2 |
Therapy interrupted, Mobility decreased, |
||||
ETANERCEPT, |
||||
| 423 | 26887786 |
CO |
89 | 2 |
Osteoporosis, Blood cholesterol increased, Mobility decreased, Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 424 | 26887964 |
CA |
33 | |
Crohn^s disease, Nausea, Dizziness, Harvey-Bradshaw index increased, Product availability issue, Therapy interrupted, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 425 | 26888157 |
US |
82 | 2 |
Rheumatoid arthritis, Back disorder, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 426 | 26888210 |
CN |
32 | 2 |
Ankylosing spondylitis, Maternal exposure during pregnancy, Off label use, Therapy interrupted, Product availability issue, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 427 | 26888471 |
CA |
27 | |
Frequent bowel movements, Condition aggravated, Illness, Off label use, Product use issue, Therapy interrupted, Drug ineffective, |
||||
USTEKINUMAB, |
||||
| 428 | 26888476 |
US |
||
Therapy interrupted, Product distribution issue, |
||||
INFLIXIMAB-DYYB, |
||||
| 429 | 26888491 |
US |
2 | |
Ankle operation, Dizziness, Therapy interrupted, Headache, Fall, Limb injury, Joint injury, Joint injury, Device difficult to use, Wrong technique in product usage process, Malaise, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, GABAPENTIN, SUMATRIPTAN SUCCINATE, NAPROXEN, NAPROXEN SODIUM, |
||||
| 430 | 26888776 |
US |
||
Psoriatic arthropathy, General symptom, Psoriasis, Therapy interrupted, Ill-defined disorder, |
||||
APREMILAST, |
||||
| 431 | 26888824 |
GB |
29 | 2 |
Rheumatoid arthritis, Therapy interrupted, Product prescribing issue, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 432 | 26889123 |
64 | 1 | |
Dizziness, Asthenia, Atrial fibrillation, Blood pressure increased, SARS-CoV-2 test positive, Therapy interrupted, |
||||
CARBOPLATIN, |
||||
| 433 | 26889261 |
US |
78 | 2 |
Coronary artery occlusion, Palpitations, Myocardial ischaemia, Anginal equivalent, Breast cancer, Mitral valve thickening, Mitral valve incompetence, Tricuspid valve incompetence, Diastolic dysfunction, Dilatation atrial, Therapy interrupted, Supraventricular extrasystoles, Off label use, Arthritis, White coat hypertension, Haemoglobin decreased, Vitamin D deficiency, Sinus tachycardia, Osteoarthritis, Essential hypertension, Osteoporosis, Depression, Generalised anxiety disorder, Fatigue, High density lipoprotein abnormal, Hyperlipidaemia, Sigmoid-shaped ventricular septum, Scan myocardial perfusion abnormal, Pain, |
||||
EVOLOCUMAB, EVOLOCUMAB, EZETIMIBE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATENOLOL, EZETIMIBE, LISINOPRIL, MAGNESIUM, CYANOCOBALAMIN, |
||||
| 434 | 26890027 |
|||
Adverse drug reaction, Therapy interrupted, |
||||
NINTEDANIB, |
||||
| 435 | 26890133 |
|||
Asthenia, Fatigue, Therapy interrupted, |
||||
TESTOSTERONE, |
||||
| 436 | 26890173 |
2 | ||
Kidney infection, Therapy interrupted, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TACROLIMUS, |
||||
| 437 | 26890177 |
1 | ||
Gallbladder operation, Therapy interrupted, |
||||
SOMATROPIN, ORAL SEMAGLUTIDE, SACUBITRIL AND VALSARTAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 438 | 26890374 |
US |
1 | |
Psoriatic arthropathy, Therapy interrupted, Surgery, |
||||
APREMILAST, |
||||
| 439 | 26890492 |
2 | ||
Infection, Adverse drug reaction, Therapy interrupted, Loss of personal independence in daily activities, Pain, |
||||
ADALIMUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, DIPHENHYDRAMINE HCL, CELECOXIB, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, ADALIMUMAB, FUROSEMIDE, PREGABALIN, |
||||
| 440 | 26890963 |
AR |
2 | |
Death, Product supply issue, Therapy interrupted, |
||||
SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, |
||||
| 441 | 26891243 |
US |
75 | 1 |
Rheumatoid arthritis, Therapy interrupted, Weight increased, Blood pressure systolic increased, Blood bilirubin increased, Feeling abnormal, |
||||
ETANERCEPT, CERTOLIZUMAB PEGOL, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, HYDROXYCHLOROQUINE SULFATE, CARVEDILOL, |
||||
| 442 | 26891485 |
US |
1 | |
Psoriatic arthropathy, Fatigue, Therapy interrupted, Psoriasis, Insurance issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, GUSELKUMAB, |
||||
| 443 | 26891544 |
US |
2 | |
Therapy interrupted, Condition aggravated, |
||||
ANIFROLUMAB-FNIA, ANIFROLUMAB-FNIA, |
||||
| 444 | 26894051 |
|||
Urinary tract infection, Therapy interrupted, |
||||
BOSENTAN, |
||||
| 445 | 26894409 |
63 | 2 | |
Therapy change, Diarrhoea, Nausea, Therapy interrupted, |
||||
LENALIDOMIDE, DARATUMUMAB, |
||||
| 446 | 26894423 |
55 | 2 | |
Pain, Loss of personal independence in daily activities, Infection, Cholecystectomy, Pancreatitis, Therapy interrupted, Illness, |
||||
ABATACEPT, CETIRIZINE HCL, CETIRIZINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 447 | 26895468 |
1 | ||
Respiratory syncytial virus infection, Therapy interrupted, |
||||
POMALIDOMIDE, |
||||
| 448 | 26896038 |
71 | 2 | |
Product use issue, Deafness, Migraine, Therapy interrupted, |
||||
MAVACAMTEN, |
||||
| 449 | 26896039 |
59 | 2 | |
Therapy interrupted, Latent tuberculosis, |
||||
ETANERCEPT, |
||||
| 450 | 26896042 |
75 | 2 | |
Therapy interrupted, Infection, |
||||
OFATUMUMAB, |
||||
| 451 | 26896043 |
78 | 1 | |
Blood sodium decreased, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 452 | 26896048 |
60 | 1 | |
Blood potassium increased, Hypertension, Therapy interrupted, |
||||
LAMIVUDINE, LAMIVUDINE ORAL, |
||||
| 453 | 26896095 |
63 | 2 | |
Pain, Hepatic neoplasm, Muscle spasms, Bone pain, Lower limb fracture, Sunburn, Nausea, Therapy interrupted, Asthenia, Insomnia, Fall, Anhedonia, |
||||
IMATINIB MESYLATE, IMATINIB, |
||||
| 454 | 26896096 |
76 | 1 | |
Fall, Hip fracture, Muscle strain, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 455 | 26881318 |
US |
26 | 2 |
Rheumatoid arthritis, Therapy interrupted, Insurance issue, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 456 | 26881491 |
CA |
72 | |
Shoulder operation, Joint range of motion decreased, Osteoarthritis, Off label use, Therapy interrupted, Inappropriate schedule of product administration, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, LORATADINE, LORATADINE ORAL, |
||||
| 457 | 26881537 |
US |
73 | 1 |
Cardiac failure congestive, Inability to afford medication, Treatment noncompliance, Therapy interrupted, |
||||
| 458 | 26881711 |
CA |
27 | |
Colitis ulcerative, Inappropriate schedule of product administration, Off label use, Product dose omission in error, Wrong product administered, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB, |
||||
| 459 | 26881845 |
US |
2 | |
Chest pain, Therapy interrupted, |
||||
| 460 | 26881983 |
US |
2 | |
Psoriasis, Product dose omission issue, Nasopharyngitis, Therapy interrupted, Hepatic lesion, Insurance issue, |
||||
BIMEKIZUMAB, RISANKIZUMAB-RZAA, GLYBURIDE, INSULIN GLARGINE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, MIDODRINE HYDROCHLORIDE, CLOPIDOGREL, PANTOPRAZOLE SODIUM, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, LEVOCETIRIZINE DIHYDROCHLORIDE, ALBUTEROL SULFATE, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, BUMETANIDE, CARVEDILOL, SACUBITRIL AND VALSARTAN, DAPAGLIFLOZIN, |
||||
| 461 | 26882068 |
CO |
23 | 1 |
Seizure, Product prescribing issue, Therapy interrupted, |
||||
LACOSAMIDE, LACOSAMIDE, LACOSAMIDE, BRIVARACETAM, BRIVARACETAM, BRIVARACETAM, |
||||
| 462 | 26882342 |
CN |
2 | |
Haematochezia, Gastric haemorrhage, Intestinal haemorrhage, Therapy interrupted, |
||||
DURVALUMAB, |
||||
| 463 | 26882544 |
CO |
22 | 1 |
Haematemesis, Product dispensing issue, Therapy interrupted, Haemoglobin abnormal, Crohn^s disease, |
||||
LACOSAMIDE, LACOSAMIDE, OXCARBAZEPINE, |
||||
| 464 | 26882697 |
CA |
25 | |
Crohn^s disease, Malaise, Off label use, Insurance issue, Product dose omission issue, Inappropriate schedule of product administration, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, AZATHIOPRINE, MESALAMINE, |
||||
| 465 | 26882978 |
US |
||
Weight increased, Therapy interrupted, |
||||
RELUGOLIX, ESTRADIOL HEMIHYDRATE, AND NORETHINDRONE ACETATE, |
||||
| 466 | 26883012 |
US |
59 | 2 |
Hidradenitis, Wrong technique in product usage process, Injection site pain, Therapy interrupted, Condition aggravated, Product availability issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 467 | 26883038 |
US |
60 | 1 |
Hot flush, Therapy interrupted, |
||||
RELUGOLIX, RELUGOLIX, |
||||
| 468 | 26883117 |
US |
63 | 1 |
Psoriatic arthropathy, Drug ineffective, Blood pressure increased, Fatigue, Dry eye, Dry mouth, Overweight, Therapy interrupted, |
||||
ETANERCEPT, APREMILAST, ALBUTEROL SULFATE, ALBUTEROL, ERGOCALCIFEROL, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, POTASSIUM CITRATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CETIRIZINE HYDROCHLORIDE, METHOTREXATE SODIUM, |
||||
| 469 | 26883391 |
US |
61 | 1 |
Anxiety, Oesophageal irritation, Gastrooesophageal reflux disease, Hiccups, Feeling abnormal, Confusional state, Memory impairment, Hypotension, Alopecia, Blood bilirubin increased, Sciatica, Endoscopy, Back pain, Rash, Hot flush, Diarrhoea, Fatigue, Dizziness, Therapy interrupted, |
||||
CAPECITABINE, CAPECITABINE, RELUGOLIX, RELUGOLIX, TAMSULOSIN HYDROCHLORIDE, FAMOTIDINE, LEUPROLIDE ACETATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, BICALUTAMIDE, ALPRAZOLAM, PROCHLORPERAZINE, DIPHENHYDRAMINE HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE ANHYDROUS, PANTOPRAZOLE, CALCIUM CARBONATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BACLOFEN, HYDROCODONE BITARTRATE, GABAPENTIN, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDICAINE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, PREDNISONE, |
||||
| 470 | 26883408 |
CO |
58 | 2 |
Arthralgia, Product dispensing issue, Gastroenteritis, Muscle spasms, Off label use, Abdominal pain upper, Arthritis, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, |
||||
| 471 | 26883570 |
US |
25 | |
Insurance issue, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, |
||||
| 472 | 26883878 |
CA |
37 | |
Rectal haemorrhage, Condition aggravated, Weight increased, Ear infection, Inappropriate schedule of product administration, Intentional dose omission, Off label use, Product dose omission issue, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, CITALOPRAM, CITALOPRAM HYDROBROMIDE, |
||||
| 473 | 26884134 |
EU |
||
Pneumonia, Therapy interrupted, |
||||
DAPAGLIFLOZIN, |
||||
| 474 | 26884786 |
US |
61 | |
Therapy interrupted, Product dose omission issue, |
||||
INFLIXIMAB-DYYB, |
||||
| 475 | 26884796 |
US |
53 | 2 |
Insurance issue, Joint swelling, Arthralgia, Therapy interrupted, Gait disturbance, |
||||
ABATACEPT, |
||||
| 476 | 26884814 |
US |
62 | |
Therapy interrupted, |
||||
DENOSUMAB, |
||||
| 477 | 26885186 |
2 | ||
Headache, Ischaemic stroke, Hypoaesthesia, Vitreous floaters, Intentional dose omission, Therapy interrupted, Insurance issue, |
||||
| 478 | 26885196 |
1 | ||
Abdominal pain upper, Fluid retention, Peripheral swelling, Dyspnoea, Therapy interrupted, Infection, Illness, |
||||
TAFAMIDIS, VUTRISIRAN, CARVEDILOL, DAPAGLIFLOZIN, FUROSEMIDE, |
||||
| 479 | 26885837 |
US |
2 | |
Drug withdrawal syndrome, Product distribution issue, Therapy interrupted, |
||||
BUPRENORPHINE, |
||||
| 480 | 26886118 |
US |
43 | 1 |
Inflammation, Therapy interrupted, Inability to afford medication, |
||||
BIMEKIZUMAB, |
||||
| 481 | 26886213 |
US |
52 | |
Loss of consciousness, Drop attacks, Therapy interrupted, Petit mal epilepsy, Seizure, |
||||
CENOBAMATE, CENOBAMATE, TOPIRAMATE, DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, SECUKINUMAB, OXYCODONE, |
||||
| 482 | 26886231 |
US |
2 | |
Migraine, Gastrointestinal disorder, Therapy interrupted, |
||||
ERENUMAB-AOOE, UBROGEPANT, |
||||
| 483 | 26888802 |
2 | ||
Therapy interrupted, Lung disorder, |
||||
AMBRISENTAN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, CARVEDILOL, SPIRONOLACTONE, LOSARTAN POTASSIUM, LOSARTAN, CALCIUM, TORSEMIDE, |
||||
| 484 | 26888809 |
60 | 2 | |
Abdominal distension, Diarrhoea, Therapy interrupted, |
||||
TENAPANOR HYDROCHLORIDE, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, ERGOCALCIFEROL, PREDNISONE, ALBUTEROL SULFATE, LUMATEPERONE, |
||||
| 485 | 26888859 |
2 | ||
Herpes zoster, Hepatic function abnormal, Therapy interrupted, |
||||
LENALIDOMIDE, ACYCLOVIR, ZOLPIDEM TARTRATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, FAMOTIDINE, FERROUS SULFATE, GABAPENTIN, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LORATADINE, LORATADINE ORAL, |
||||
| 486 | 26889412 |
35 | 2 | |
Hospitalisation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 487 | 26890021 |
72 | 2 | |
Therapy interrupted, Gait inability, Balance disorder, Spinal cord compression, Gait disturbance, Pain, |
||||
IXEKIZUMAB, |
||||
| 488 | 26895645 |
74 | 2 | |
Urinary tract infection, Sepsis, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 489 | 26896030 |
59 | 2 | |
Tumour marker increased, Drug resistance, Therapy interrupted, Hypokalaemia, Hypomagnesaemia, Upper respiratory tract infection, Feeling abnormal, Diarrhoea, |
||||
CARBOPLATIN, DOXORUBICIN HYDROCHLORIDE, |
||||
| 490 | 26875998 |
GB |
1 | |
Hospitalisation, Dysphagia, Therapy interrupted, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 491 | 26876083 |
US |
2 | |
Psoriatic arthropathy, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 492 | 26876284 |
US |
34 | 1 |
Back pain, Therapy interrupted, General physical health deterioration, |
||||
ETANERCEPT, |
||||
| 493 | 26876366 |
US |
||
Suicidal ideation, Anxiety, Panic attack, Therapy interrupted, |
||||
GLYCOPYRROLATE AND FORMOTEROL FUMARATE, |
||||
| 494 | 26876629 |
US |
63 | 1 |
Arthralgia, Feeling abnormal, Drug dose omission by device, Device difficult to use, Migraine, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 495 | 26876820 |
CA |
52 | |
Injection site nerve damage, Drug ineffective, Therapy interrupted, Inappropriate schedule of product administration, Harvey-Bradshaw index increased, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, IRBESARTAN, TAMSULOSIN HYDROCHLORIDE, |
||||
| 496 | 26876943 |
GB |
1 | |
Lower respiratory tract infection, Ankylosing spondylitis, Uveitis, Nasopharyngitis, Therapy interrupted, Unevaluable event, Musculoskeletal stiffness, Inappropriate schedule of product administration, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 497 | 26876972 |
CA |
36 | |
Condition aggravated, Infusion related reaction, Maternal exposure during pregnancy, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, PREDNISONE, |
||||
| 498 | 26876973 |
US |
85 | 1 |
Hypoacusis, Therapy interrupted, |
||||
RELUGOLIX, RELUGOLIX, EZETIMIBE, FENOFIBRATE, ATORVASTATIN CALCIUM, LISINOPRIL, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, DENOSUMAB, RIVAROXABAN, |
||||
| 499 | 26877075 |
GB |
56 | |
Crohn^s disease, Therapy interrupted, |
||||
USTEKINUMAB, |
||||
| 500 | 26877318 |
JP |
||
Therapy interrupted, |
||||
UMECLIDINIUM, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30